Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy

Area of Science:

• Oncology
• Cancer Biology
• Vascular Biology

Background:

• Chondrosarcomas (ChSs) are chemo- and radiation-resistant bone tumors.
• Inoperable or metastatic ChS presents a significant clinical challenge due to limited therapeutic options.
• Vasculogenic mimicry (VM) is a process where tumor cells form vascular-like structures.

Purpose of the Study:

• To investigate the presence of VM in human ChS tissues.
• To elucidate the role of Urokinase Plasminogen Activator Receptor (uPAR) in ChS VM.
• To evaluate the efficacy of targeting uPAR against ChS VM.

Main Methods:

• Analysis of human ChS tissues for vascular-like channels.
• In vitro studies using patient-derived ChS cells and a ChS cell line to assess tubule formation.
• Assessment of uPAR's role in mediating VM.
• Testing the effect of bevacizumab and a uPAR-derived peptide (RI-3) on VM.

Main Results:

• CD-31- and Podoplanin-negative vascular-like channels containing red blood cells were identified in human ChS tissues, suggesting VM.
• ChS cells demonstrated the ability to form in vitro tubules.
• uPAR was identified as a key mediator of VM in ChS cells.
• The uPAR-derived peptide RI-3 potently inhibited VM, whereas bevacizumab had no effect.

Conclusions:

• This study provides the first evidence of VM in human ChS tissues.
• uPAR plays a critical role in enabling ChS cells to form VM.
• The uPAR-targeting peptide RI-3 shows potential as a therapeutic agent against ChS by inhibiting VM.